Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

TransCode Therapeutics ( (RNAZ) ) has shared an announcement.

TransCode Therapeutics (NASDAQ:RNAZ) will execute its previously announced 1-for-33 reverse stock split on Dec. 4, 2024. The company’s common stock is expected to begin trading on a split-adjusted ...

TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse ...

In connection with the reverse stock split, the Company's CUSIP number will change to 89357L402 as of 12:01 a.m. Eastern Standard Time on December 4, 2024. About TransCode Therapeutics TransCode ...

Transcode Therapeutics shares are trading lower by 11% to 34 cents Monday afternoon. The company announced its Board's ...

TransCode Therapeutics (RNAZ) Board of Directors has approved a 1-for-33 reverse stock split. The reverse stock split was approved by TransCode’s stockholders on November 22, 2024, and is ...

RNA oncology company TransCode Therapeutics has developed a modular, iron oxide nanoparticle–based nanocarrier system for the delivery of RNA therapeutics to tumors. The platform overcomes ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical-stage oncology company, announced today that its Board of Directors has approved a 1-for-33 reverse stock split. The decision ...

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company: At our upcoming ...

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...